ZKB/CALL/ELI LILLY & CO/1100/0.01/27.06.25 | Real-time Bid/Ask 04:16:37 2024-07-11 am EDT | ||
| 0.73 CHF / 0.74 CHF | +5.00% |
|
| Current month | +12.90% | ||
| 1 month | +48.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-10 | 0.7 | +6.06% |
| 24-07-09 | 0.66 | +3.13% |
| 24-07-08 | 0.64 | +3.23% |
| 24-07-05 | 0.62 | +8.77% |
| 24-07-04 | 0.57 | +3.64% |
Delayed Quote Swiss Exchange
Last update July 10, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | ZKB |
| LLYBYZ | |
| ISIN | CH1338507572 |
| Date issued | 2024-05-28 |
| Strike | 1,100 $ |
| Maturity | 2025-06-27 (352 Days) |
| Parity | 100 : 1 |
| Emission price | 0.42 CHF |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.7 CHF |
|---|---|
| Lowest since issue | 0.38 CHF |
| Spread | 0.01 CHF |
| Spread % | 1.35% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
939.8
USD
Average target price
874.8
USD
Spread / Average Target
-6.92%
- Stock Market
- Warrants
- LLYBYZ Warrant
